Peter Cancelmo Sells 25,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the transaction, the vice president directly owned 200 shares of the company’s stock, valued at approximately $3,708. The trade was a 99.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Omeros Price Performance

Shares of Omeros stock traded down $0.04 during midday trading on Tuesday, hitting $18.75. 2,042,181 shares of the company were exchanged, compared to its average volume of 1,711,567. The firm has a 50 day simple moving average of $12.81 and a 200-day simple moving average of $12.08. The firm has a market cap of $1.36 billion, a P/E ratio of 14.65 and a beta of 2.54. Omeros Corporation has a 52 week low of $3.94 and a 52 week high of $19.65.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. Equities research analysts expect that Omeros Corporation will post -0.37 earnings per share for the current year.

Institutional Trading of Omeros

Large investors have recently made changes to their positions in the business. UBS Group AG lifted its position in Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after buying an additional 1,513,893 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Omeros by 85.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock worth $1,897,000 after acquiring an additional 82,646 shares during the last quarter. BlackRock Inc. acquired a new stake in Omeros in the 2nd quarter valued at about $57,484,000. Ancora Advisors LLC acquired a new stake in Omeros in the 2nd quarter valued at about $1,605,000. Finally, Deutsche Bank AG bought a new position in shares of Omeros in the second quarter worth about $714,000. Institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on OMER. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Finally, Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $38.00.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.